Abstract: A connection structure of a superconducting layer according to an embodiment includes a first superconducting layer, a second superconducting layer, and a connection layer provided between the first superconducting layer and the second superconducting layer and including a first substance containing a rare earth element, barium, copper, and oxygen and a second substance containing a metal element, in which a first region per unit area at a first interface between the first superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the first superconducting layer are in contact with each other, and a second region per unit area at a second interface between the second superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the second superconducting layer are in contact with each other.

Abstract: A superconducting layer joint structure of embodiments includes: a first superconducting layer; a second superconducting layer; and a joint layer provided between the first superconducting layer and the second superconducting layer and containing a plurality of crystal particles containing a rare earth element (RE), barium (Ba), copper (Cu), and oxygen (O). The plurality of crystal particles includes at least one first particle. The at least one first particle has a first inner region and a first outer region. The first inner region is disposed inside the first superconducting layer. The first outer region is disposed outside the first superconducting layer.

Abstract: A problem of the present invention is to provide a method capable of avoiding nonspecific reactions which result in the absence of agglutination that should occur in agglutination inhibition LTIA. The present invention provides a method of avoiding nonspecific reactions in a latex agglutination inhibition test by performing a latex agglutination inhibition assay in the presence of one or more compounds selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, and polyvalent quaternary amine polymer compounds.

Abstract: Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.

Abstract: A problem of the present invention is to provide a method capable of avoiding nonspecific reactions which result in the absence of agglutination that should occur in agglutination inhibition LTIA. The present invention provides a method of avoiding nonspecific reactions in a latex agglutination inhibition test by performing a latex agglutination inhibition assay in the presence of one or more compounds selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, and polyvalent quaternary amine polymer compounds.

Abstract: Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.